Equipoise – Boldenone Undecylenate (Bold200, Boldenone, Baldebal-H)
Ciccone Equipoise Combo450 (See Boldenone esters: Undecylenate, see Cypionate, Acetate)
Primabolin Tabs – Methenolone Acetate
Primabolin Depot – Methenolone Enathate (Alphabolin, Primabolin Depot)
Masteron100 – Drostanalone Propionate
Masteron200 – Drostanolone Enanthate
Winstrol Depot – Stanozolol
Winstrol Tabs – Stanozolol
Oxandrolone – Oxandrolone (Anavar)
Mesterolone (Proviron) is a purely androgenic steroid with no anabolic qualities. The drug was used both as an anti-estrogen that "prevents" estrogen from being produced through the aromatization of sex steroids, and for its hardening effect upon musculature. Unlike Nolvadex (which only keeps estrogen from bonding with its receptors by blocking them), Proviron actually prevents the formation of estrogen. Due to lower estrogen levels, athletes retained less water and prevented (for the most part) the formation of gyno and female pattern fat deposits.
American Medical Association, Council on Scientific Affairs. Medical and non-medical uses of anabolic-androgenic steroids. J. Amer. Med. Assoc. 264: 2923-2927, 1990.
Bahrke, ., . Yesalosk, and . Wright. Psychological and behavioural effects of endogenous testosterone levels and anabolic-androgenic steroids among males: a review. Sports Med. 10: 303-337, 1990.
Buckley, ., . Yasalis, . Friedl, . Anderson, . Streit, and . Wright. Estimated prevalance of anabolic steroid use among male high school seniors. J. Amer. Med. Assoc. 260: 3441-3445, 1988.
Rogozkin, V. Metabolism of Anabolic Androgenic Steroids. Leningrad: Nauka, 1988.
United States Olympic Committee. USOC Drug Education Handbook. Colorado Springs: USOC, 1989.
Assessment of Aggressive Behavior and Plasma Testosterone in a Young Criminal PopulationLeo E. Kreuz, MD, MAJ, MCand Robert M. Rose, MD, June 23, 1971. Revision received December 1, 1971. 1972 American Psychosomatic Society
BEHRE, ., K. ABSHAGEN, M. OETTEL, D. HUBLER AND E. NIESCHLAG. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. Eur J Endocrinol 140:414 ***8211; 419. 1999